IP Library Patent Application 12090434
Patent Application
App. No. 12/090,434

COMPOSITIONS AND TREATMENTS FOR INHIBITING KINASE AND/OR HMG-COA REDUCTASE

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
12/090,434
Abstract

The present invention provides compositions of matter, kits and methods for their use in the treatment of MAP kinase-related conditions and/or HMG-CoA reductase-related conditions. In particular, the invention provides compositions for treating inflammatory and/or cardiovascular conditions in an animal subject by inhibiting p38αMAP kinase and/or HMG-CoA reductase, as well as providing formulations and modes of administering such compositions. The invention further provides methods for the rational design of inhibitors of MAP kinase, HMG-CoA reductase, or both for use in the practice of the present invention.

Claims (19)

1 . A method of inhibiting a MAP kinase comprising administering an effective amount of at least one compound comprising of formula XXXII:

wherein R 1 is

n being 0 or any integer;

R 2 is optionally substituted alkyl, cycloalkyl, aryl, or heteroaryl;

R 4 is optionally substituted

and R 5 is hydrogen, optionally substituted lower alkyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, halogen, cyano, hydroxy, optionally substituted lower alkoxy, optionally substituted alkaryl, optionally substituted alkheteroaryl, optionally substituted amido, optionally substituted carboxamido, optionally substituted sulfonamide, optionally substituted amidosulfonyl, or optionally substituted amino, or a pharmaceutically acceptable salt thereof.

2 . The method as recited in claim 1 wherein said R 1 has the following stereochemistry:

3 . The method as recited in claim 1 wherein said inhibited MAP kinase is p38 MAP kinase.

4 . The method as recited in claim 1 , further comprising inhibiting an HMG CoA reductase.

5 . The method as recited in claim 1 wherein said administering treats a MAP kinase-related condition.

6 . The method as recited in claim 1 wherein said administering treats a MAP kinase-related condition and an HMG CoA reductase-related condition.

7 . The method as recited in claim 1 wherein said administering treats an inflammatory condition.

8 . A compound of formula XXXII:

wherein R 1 is

n being 0 or any integer;

R 2 is optionally substituted alkyl, cycloalkyl, aryl, or heteroaryl;

R 4 is optionally substituted

and R 5 is hydrogen, optionally substituted lower alkyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, halogen, cyano, hydroxy, optionally substituted lower alkoxy, optionally substituted alkaryl, optionally substituted alkheteroaryl, optionally substituted amido, optionally substituted carboxamido, optionally substituted sulfonamide, optionally substituted amidosulfonyl, or optionally substituted amino, or a pharmaceutically acceptable salt thereof.

9 . A compound comprising at least one structure selected from:

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 18, 2009
From: GRIFFIN, JOHN; LANZA, GUIDO; YU, JESSEN
To: NUMERATE, INC.
Reel/Frame 022415/0315 →